Tamiami Angel Fund II (T2) invested $930,000 in Catalyst OrthoScience, developer of a shoulder replacement system.
The Catalyst CSR Shoulder is designed to replicate the shape of a normal shoulder more closely than currently-available devices. CSR is also reportedly smaller and requires less bone removal than current procedures for joint replacement. The system received FDA 510(k) clearance in May 2016.
T2 was also the lead investor in Catalyst OrthoScience’s $3.3MM capital raise, its first significant round of funding from outside investors.
Other companies with partial or resurfacing shoulder devices include ArthroSurface (HemiCAP), DePuy (Global CAP and Anchor Peg Glenoid), Exactech (Equinoxe), Wright Medical (Aequalis PerFORM) and Zimmer Biomet (Copeland Resurfacing Heads).
Sources: Tamiami Angel Funds; ORTHOWORLD Inc.
Tamiami Angel Fund II (T2) invested $930,000 in Catalyst OrthoScience, developer of a shoulder replacement system.
The Catalyst CSR Shoulder is designed to replicate the shape of a normal shoulder more closely than currently-available devices. CSR is also reportedly smaller and requires less bone removal than current procedures for joint...
Tamiami Angel Fund II (T2) invested $930,000 in Catalyst OrthoScience, developer of a shoulder replacement system.
The Catalyst CSR Shoulder is designed to replicate the shape of a normal shoulder more closely than currently-available devices. CSR is also reportedly smaller and requires less bone removal than current procedures for joint replacement. The system received FDA 510(k) clearance in May 2016.
T2 was also the lead investor in Catalyst OrthoScience’s $3.3MM capital raise, its first significant round of funding from outside investors.
Other companies with partial or resurfacing shoulder devices include ArthroSurface (HemiCAP), DePuy (Global CAP and Anchor Peg Glenoid), Exactech (Equinoxe), Wright Medical (Aequalis PerFORM) and Zimmer Biomet (Copeland Resurfacing Heads).
Sources: Tamiami Angel Funds; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
